Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Sailish Honap; Robin J. Dart; Mark A. Samaan

doi:10.1111/apt.16761

King's College London

King's main site

Research portal

Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Research output: Contribution to journal › Article › peer-review

Sailish Honap, Robin J. Dart, Mark A. Samaan

Original language	English
Pages (from-to)	733-734
Number of pages	2
Journal	Alimentary Pharmacology & Therapeutics
Volume	55
Issue number	6
Early online date	4 Mar 2022
DOIs	https://doi.org/10.1111/apt.16761
E-pub ahead of print	4 Mar 2022
Published	Mar 2022
Additional links	Link to publication in Scopus

Bibliographical note

Funding Information: Declaration of personal interest: Sailish Honap served as a speaker, a consultant, and/or an advisory board member for Pfizer, Janssen, and Takeda. Robin Dart has received research support and/or has received fees for the delivery of non-promotional education or consulting from Gamma Delta Therapeutics, Adaptate Biotherapeutics, Takeda and Janssen. Mark Samaan served as a speaker, a consultant and/or an advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Abbvie, Bristol Myers Squibb and Samsung Bioepis.

King's Authors

View graph of relations

King's College London - Homepage

Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Bibliographical note

King's Authors

By the same authors

With some of the same researchers

From the same journal